ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE

7938 reported adverse events

Drug classes: Cytochrome P450 3A Inhibitor [EPC] Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC] Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

These side effects are most commonly reported by patients taking ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE:

# Side effect Count
0 BONE DENSITY DECREASED 3697
1 CHRONIC KIDNEY DISEASE 2047
2 BONE LOSS 1974
3 OSTEONECROSIS 1965
4 TOOTH LOSS 1822
5 RENAL INJURY 1753
6 MULTIPLE FRACTURES 1728
7 RENAL FAILURE 1613
8 OSTEOPOROSIS 1517
9 SKELETAL INJURY 1503
See all common reactions for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE

ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 ALOPECIA SYPHILITIC 1 1.0000
1 BONE LOSS 1974 0.1604
2 SKELETAL INJURY 1503 0.1587
3 CIRCULATING ANTICOAGULANT 2 0.1429
4 BONE DENSITY DECREASED 3697 0.1399
5 MULTIPLE FRACTURES 1728 0.1287
6 PLETHORIC FACE 2 0.1250
7 HIV-ASSOCIATED NEUROCOGNITIVE DISORDER 10 0.1235
8 SYSTEMIC VIRAL INFECTION 3 0.1200
9 DEGENERATIVE BONE DISEASE 27 0.1144
See all enriched reactions for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE